Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening

Journal of Medicinal Chemistry

Volumn 58, Issue 6, 2015, Pages 2799-2808

  Cheney, Daniel L ^a   Bozarth, Jeffrey M ^a   Metzler, William J ^a   Morin, Paul E ^a   Mueller, Luciano ^a   Newitt, John A ^a   Nirschl, Alexandra H ^a   Rendina, Alan R ^a   Tamura, James K ^a   Wei, Anzhi ^a   Wen, Xiao ^a   Wurtz, Nicholas R ^a   Seiffert, Dietmar A ^a   Wexler, Ruth R ^a   Priestley, E Scott ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYL HALIDE DERIVATIVE; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; HETEROCYCLE DERIVATIVE; LACTAM; UNCLASSIFIED DRUG; HALOGEN; HETEROCYCLIC COMPOUND; SERINE PROTEINASE INHIBITOR;

ARTICLE; CRYSTALLOGRAPHY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; NUCLEAR MAGNETIC RESONANCE; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR DOCKING; X RAY CRYSTALLOGRAPHY;

BLOOD COAGULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FACTOR VIIA; HALOGENS; HETEROCYCLIC COMPOUNDS; HUMANS; LACTAMS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; SERINE PROTEINASE INHIBITORS;

EID: 84925935684     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501982k     Document Type: Article

References (76)

1. WHO, Global status report on noncommunicable diseases; WHO Publishing: Geneva, 2010.
2. Levi, M.; Eerenberg, E.; Kamphuisen, P. W. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents Thromb. Haemostasis 2011, 9 (9) 1705-1712
3. Wallentin, L.; Wilcox, R. G.; Weaver, W. D.; Emanuelsson, H.; Goodvin, A.; Nystrom, P.; Bylock, A. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 2003, 362 (9386) 789-797
4. Mega, J. L.; Braunwald, E.; Wiviott, S. D.; Bassand, J. P.; Bhatt, D. L.; Bode, C.; Burton, P.; Cohen, M.; Cook-Bruns, N.; Fox, K. A.; Goto, S.; Murphy, S. A.; Plotnikov, A. N.; Schneider, D.; Sun, X.; Verheugt, F. W.; Gibson, C. M. Rivaroxaban in patients with a recent acute coronary syndrome N. Engl. J. Med. 2012, 366 (1) 9-19
5. Tricoci, P.; Huang, Z.; Held, C.; Moliterno, D. J.; Armstrong, P. W.; Van de Werf, F.; White, H. D.; Aylward, P. E.; Wallentin, L.; Chen, E.; Lokhnygina, Y.; Pei, J.; Leonardi, S.; Rorick, T. L.; Kilian, A. M.; Jennings, L. H. K.; Ambrosio, G.; Bode, C.; Cequier, A.; Cornel, J. H.; Diaz, R.; Erkan, A.; Huber, K.; Hudson, M. P.; Jiang, L.; Jukema, J. W.; Lewis, B. S.; Lincoff, A. M.; Montalescot, G.; Nicolau, J. C.; Ogawa, H.; Pfisterer, M.; Prieto, J. C.; Ruzyllo, W.; Sinnaeve, P. R.; Storey, R. F.; Valgimigli, M.; Whellan, D. J.; Widimsky, P.; Strony, J.; Harrington, R. A. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N. Engl. J. Med. 2012, 366 (1) 20-33
6. Granger, C. B.; Alexander, J. H.; McMurray, J. J.; Lopes, R. D.; Hylek, E. M.; Hanna, M.; Al-Khalidi, H. R.; Ansell, J.; Atar, D.; Avezum, A.; Bahit, M. C.; Diaz, R.; Easton, J. D.; Ezekowitz, J. A.; Flaker, G.; Garcia, D.; Geraldes, M.; Gersh, B. J.; Golitsyn, S.; Goto, S.; Hermosillo, A. G.; Hohnloser, S. H.; Horowitz, J.; Mohan, P.; Jansky, P.; Lewis, B. S.; Lopez-Sendon, J. L.; Pais, P.; Parkhomenko, A.; Verheugt, F. W.; Zhu, J.; Wallentin, L. Apixaban versus warfarin in patients with atrial fibrillation N Engl J. Med. 2011, 365 (11) 981-992
7. Wong, P. C.; Luettgen, J. M.; Rendina, A. R.; Kettner, C. A.; Xin, B.; Knabb, R. M.; Wexler, R.; Priestley, E. S. BMS-593214, an active site-directed factor VIIa inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studies Thromb. Haemostasis 2010, 104 (2) 261-269
8. Lazarus, R. A.; Olivero, A. G.; Eigenbrot, C.; Kirchhofer, D. Inhibitors of tissue factor•factor VIIa for anticoagulant therapy Curr. Med. Chem. 2004, 11, 2275-2290
9. Suleymanov, O. D.; Szalony, J. A.; Salyers, A. K.; Lachance, R. M.; Parlow, J. J.; South, M. S.; Wood, R. S.; Nicholson, N. S. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model J. Pharmacol. Exp. Ther. 2003, 306, 1115-1121
10. Szalony, J. A.; Suleymanov, O. D.; Salyers, A. K.; Panzer-Knodle, S. G.; Blom, J. D.; LaChance, R. M.; Case, B. L.; Parlow, J. J.; South, M. S.; Wood, R. S.; Nicholson, N. S. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: Effects on thrombus formation and bleeding time Thromb Res. 2003, 112, 167-174
11. Salyers, A. K.; Szalony, J. A.; Suleymanov, O. D.; Parlow, J. J.; Wood, R. S.; South, M. S.; Nicholson, N. S. Assessment of bleeding propensity in non-human primates by combination of selective tissue factor/VIIa inhibition and aspirin compared to warfarin and aspirin treatment Pharmacology 2004, 70, 100-106
12. Szalony, J. A.; Taite, B. B.; Girard, T. J.; Nicholson, N. S.; LaChance, R. M. Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis J. Thromb. Thrombolysis 2002, 14 (2) 113-121
13. Dennis, M. S.; Eigenbrot, C.; Skelton, N. J.; Ultsch, M. H.; Santell, L.; Dwyer, M. A.; OConnell, M. P.; Lazarus, R. A. Peptide exosite inhibitors of factor VIIa as anticoagulants Nature 2000, 404, 465-470
14. Ruf, W.; Dickinson, C. D. Allosteric regulation of the cofactor-dependent serine protease coagulation factor VIIa Trends Cardiovasc. Med. 1998, 8 (8) 350-356
15. Rand, K. D.; Jorgensen, T. J.; Olsen, O. H.; Persson, E.; Jensen, O. N.; Stennicke, H. R.; Andersen, M. D. Allosteric activation of coagulation factor VIIa visualized by hydrogen exchange J. Biol. Chem. 2006, 281 (32) 23018-23024
16. Persson, E.; Olsen, O. H. Allosteric activation of coagulation factor VIIa Front. Biosci., Landmark Ed. 2011, 16, 3156-3163
17. Kelley, R. F.; Yang, J.; Eigenbrot, C.; Moran, P.; Peek, M.; Lipari, M. T.; Kirchhofer, D. Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity Biochemistry 2004, 43 (5) 1223-1229
18. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain Biochem. Biophys. Res. Commun. 1967, 27 (2) 157-162
19. Banner, D. W. Principles of enzyme-inhibitor design Methods Princ. Med. Chem. 2003, 19, 163-185
20. Although the structure of the Michaelis factor VIIa/substrate complex is unknown, the subsites S1′, S1, S2, etc. binding P1′, P1, P2, etc. substrate amino acids can be inferred from crystallographic structures of factor VIIa bound with peptide-like structures. See, for example, the crystallographic structures of several tripeptide mimetics bound to factor VIIa, PDBID 1W0Y, 1W2K, 1W7X, 1W8B, 1WQV, 1WSS, 1WTG, 1WUN, and 1WV7, as well as BPTI bound to factor VIIa (PDBID 1FAK).
21. Bolton, S. A.; Sutton, J. C.; Anumula, R.; Bisacchi, G. S.; Jacobson, B.; Slusarchyk, W. A.; Treuner, U. D.; Wu, S. C.; Zhao, G.; Pi, Z.; Sheriff, S.; Smirk, R. A.; Bisaha, S.; Cheney, D. L.; Wei, A.; Schumacher, W. A.; Hartl, K. S.; Liu, E.; Zahler, R.; Seiler, S. M. Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold Bioorg. Med. Chem. Lett. 2013, 23 (18) 5239-5243
22. Rautio, J. Prodrugs and Targeted Delivery: Towards Better ADME Properties. John Wiley & Sons: Weinheim, Germany, 2011.
23. Pinto, D. J. P.; Orwat, M. J.; Wang, S.; Fevig, J. M.; Quan, M. L.; Amparo, E.; Cacciola, J.; Rossi, K. A.; Alexander, R. S.; Smallwood, A. M.; Luettgen, J. M.; Liang, L.; Aungst, B. J.; Wright, M. R.; Knabb, R. M.; Wong, P. C.; Wexler, R. R.; Lam, P. Y. S. Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)- [1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa1 J. Med. Chem. 2001, 44 (4) 566-578
24. Kotthaus, J.; Hungeling, H.; Reeh, C.; Kotthaus, J.; Schade, D.; Wein, S.; Wolffram, S.; Clement, B. Synthesis and biological evaluation of l-valine-amidoximeesters as double prodrugs of amidines Bioorg. Med. Chem. 2011, 19 (6) 1907-1914
25. Zhang, X.; Jiang, W.; Jacutin-Porte, S.; Glunz, P. W.; Zou, Y.; Cheng, X.; Nirschl, A. H.; Wurtz, N. R.; Luettgen, J. M.; Rendina, A. R.; Luo, G.; Harper, T. M.; Wei, A.; Anumula, R.; Cheney, D. L.; Knabb, R. M.; Wong, P. C.; Wexler, R. R.; Priestley, E. S. Design and synthesis of phenylpyrrolidine phenylglycinamides as highly potent and selective TF-FVIIA inhibitors ACS Med. Chem. Lett. 2014, 5 (2) 188-192
26. Katz, B. A.; Sprengeler, P. A.; Luong, C.; Verner, E.; Elrod, K.; Kirtley, M.; Janc, J.; Spencer, J. R.; Breitenbucher, J. G.; Hui, H.; McGee, D.; Allen, D.; Martelli, A.; Mackman, R. L. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets Chem. Biol. 2001, 8 (11) 1107-1121
27. Perona, J. J.; Evnin, L. B.; Craik, C. S. A genetic selection elucidates structural determinants of arginine versus lysine specificity in trypsin Gene 1993, 137 (1) 121-126
28. Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and Synthesis of a Series of Potent and Orally Bioavailable Noncovalent Thrombin Inhibitors That Utilize Nonbasic Groups in the P1 Position J. Med. Chem. 1998, 41, 3210-3219
29. Orwat, M. J.; Rossi, K. A.; Luettgen, J.; Knabb, R. M.; He, K.; Wexler, R. R.; Lam, P. Y. S.; Pinto, D. J. Discovery of pyrazole based geminally substituted p4 groups as potent, selective, and orally bioavailable inhibitors of blood coagulation factor xa. Abstracts of Papers, 238th ACS National Meeting; American Chemical Society: Washington, DC, 2009; MEDI-436.
30. Qiao, J. X.; Cheney, D. L.; Alexander, R. S.; Smallwood, A. M.; King, S. R.; He, K.; Rendina, A. R.; Luettgen, J. M.; Knabb, R. M.; Wexler, R. R.; Lam, P. Y. S. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa Bioorg. Med. Chem. Lett. 2008, 18 (14) 4118-4123
31. Corte, J. R.; Fang, T.; Pinto, D. J. P.; Han, W.; Hu, Z.; Jiang, X.-J.; Li, Y.-L.; Gauuan, J. F.; Hadden, M.; Orton, D.; Rendina, A. R.; Luettgen, J. M.; Wong, P. C.; He, K.; Morin, P. E.; Chang, C.-H.; Cheney, D. L.; Knabb, R. M.; Wexler, R. R.; Lam, P. Y. S. Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties Bioorg. Med. Chem. Lett. 2008, 18 (9) 2845-2849
32. Qiao, J. X.; Wang, T. C.; Wang, G. Z.; Cheney, D. L.; He, K.; Rendina, A. R.; Xin, B.; Luettgen, J. M.; Knabb, R. M.; Wexler, R. R.; Lam, P. Y. S. Enantiopure five-membered cyclic diamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications Bioorg. Med. Chem. Lett. 2007, 17 (18) 5041-5048
33. Pinto, D. J. P.; Orwat, M. J.; Koch, S.; Rossi, K. A.; Alexander, R. S.; Smallwood, A.; Wong, P. C.; Rendina, A. R.; Luettgen, J. M.; Knabb, R. M.; He, K.; Xin, B.; Wexler, R. R.; Lam, P. Y. S. Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl]phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa J. Med. Chem. 2007, 50 (22) 5339-5356
34. Maignan, S.; Guilloteau, J. P.; Choi-Sledeski, Y. M.; Becker, M. R.; Ewing, W. R.; Pauls, H. W.; Spada, A. P.; Mikol, V. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: Preference for a neutral group in the S1 pocket J. Med. Chem. 2003, 46 (5) 685-690
35. Blaney, J.; Nienaber, V.; Burley, S. K., Fragment-based Lead Discovery and Optimization Using X-Ray Crystallography, Computational Chemistry, and High-throughput Organic Synthesis. In Fragment-based Approaches in Drug Discovery; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2006; pp 215-248.
36. Available Chemicals Directory; Accelrys, I., 5005 Wateridge Vista Drive, San Diego, CA 92121, USA; accelrys.com.
37. Pipeline Pilot; Accelrys, I., 5005 Wateridge Vista Drive, San Diego, CA 92121, USA; accelrys.com.
38. Carhart, R. E.; Smith, D. H.; Venkataraghavan, R. Atom pairs as molecular features in structure-activity studies: definition and applications J. Chem. Inf. Comput. Sci. 1985, 25 (2) 64-73
39. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P.; Mainz, D. T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-ligand Complexes J. Med. Chem. 2006, 49 (21) 6177-6196
40. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy J. Med. Chem. 2004, 47 (7) 1739-1749
41. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening J. Med. Chem. 2004, 47 (7) 1750-1759
42. Mueller, L.; Cheney, D. L. Protein ensemble docking: An effective strategy for enhanced lead docking. Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1; American Chemical Society: Washington, DC, 2005; COMP-063.
43. Mueller, L.; Cheney, D. L. Toward the development of an accurate virtual screening protocol: Recent improvements in protein ensemble docking. Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1; American Chemical Society: Washington, DC, 2005; COMP- 163.
44. Mueller, L.; Langley, D. R.; Cheney, D. L. In Lead docking protocol featuring improved sampling and scoring, Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26; American Chemical Society: Washington, DC, 2004; COMP- 245.
45. Cheney, D. L.; Langley, D. R.; Mueller, L. Protein ensemble-based lead docking: A comparison of FLO, GLIDE, GOLD and ICM in cross docking scenarios. Abstracts of Papers, 227th ACS National Meeting, Anaheim, CA, United States, March 28-April 1; American Chemical Society: Washington, DC, 2004; COMP- 293.
46. The PyMOL Molecular Graphics System, Version 1.5.0.4, Schrodinger, LLC.
47. Schrodinger Release 2013-3, Maestro, version 9.6, Schrodinger, LLC, New York, NY, 2013.
48. Ennifar, E.; Carpentier, P.; Ferrer, J.-L.; Walter, P.; Dumas, P. X-ray-induced debromination of nucleic acids at the Br K absorption edge and implications for MAD phasing Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58 (8) 1262-1268
49. Schiltz, M.; Dumas, P.; Ennifar, E.; Flensburg, C.; Paciorek, W.; Vonrhein, C.; Bricogne, G. Phasing in the presence of severe site-specific radiation damage through dose-dependent modelling of heavy atoms Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60 (Pt 6) 1024-1031
50. Burmeister, W. P. Structural changes in a cryo-cooled protein crystal owing to radiation damage Acta Crystallogr., Sect. D: Biol. Crystallogr. 2000, 56 (3) 328-341
51. Bruno, I. J.; Cole, J. C.; Edgington, P. R.; Kessler, M.; Macrae, C. F.; McCabe, P.; Pearson, J.; Taylor, R. New software for searching the Cambridge Structural Database and visualizing crystal structures Acta Crystallogr. B 2002, 58 (Pt 3 Pt 1) 389-397
52. Cheney, D. L.; Rossi, K. A. Evaluation of several correlated electronic methods in the context of calculations common to drug design. Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10; American Chemical Society: Washington, DC, 2008; COMP-22.
53. Cheney, D. L.; Rossi, K. A. Comparison of DFT and MP2-based electronic models in the estimation of relative conformational and tautomeric energies and torsional potentials of drug-like moieties. Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10; American Chemical Society: Washington, DC, 2008; COMP-143.
54. Shao, Y.; Molnar, L. F.; Jung, Y.; Kussmann, J.; Ochsenfeld, C.; Brown, S. T.; Gilbert, A. T.; Slipchenko, L. V.; Levchenko, S. V.; ONeill, D. P.; DiStasio, R. A., Jr.; Lochan, R. C.; Wang, T.; Beran, G. J.; Besley, N. A.; Herbert, J. M.; Lin, C. Y.; Van Voorhis, T.; Chien, S. H.; Sodt, A.; Steele, R. P.; Rassolov, V. A.; Maslen, P. E.; Korambath, P. P.; Adamson, R. D.; Austin, B.; Baker, J.; Byrd, E. F.; Dachsel, H.; Doerksen, R. J.; Dreuw, A.; Dunietz, B. D.; Dutoi, A. D.; Furlani, T. R.; Gwaltney, S. R.; Heyden, A.; Hirata, S.; Hsu, C. P.; Kedziora, G.; Khalliulin, R. Z.; Klunzinger, P.; Lee, A. M.; Lee, M. S.; Liang, W.; Lotan, I.; Nair, N.; Peters, B.; Proynov, E. I.; Pieniazek, P. A.; Rhee, Y. M.; Ritchie, J.; Rosta, E.; Sherrill, C. D.; Simmonett, A. C.; Subotnik, J. E.; Woodcock, H. L., 3rd; Zhang, W.; Bell, A. T.; Chakraborty, A. K.; Chipman, D. M.; Keil, F. J.; Warshel, A.; Hehre, W. J.; Schaefer, H. F., 3rd; Kong, J.; Krylov, A. I.; Gill, P. M.; Head-Gordon, M. Advances in methods and algorithms in a modern quantum chemistry program package Phys. Chem. Chem. Phys. 2006, 8 (27) 3172-3191
55. Burgi, H. B.; Dunitz, J. D.; Lehn, J. M.; Wipff, G. Stereochemistry of reaction paths at carbonyl centres Tetrahedron 1974, 30 (12) 1563-1572
56. Friesner, R. A. Private communication, 2004.
57. Fischer, F. R.; Wood, P. A.; Allen, F. H.; Diederich, F. Orthogonal dipolar interactions between amide carbonyl groups Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (45) 17290-17294
58. Kamer, K. J.; Choudhary, A.; Raines, R. T. Intimate Interactions with Carbonyl Groups: Dipole-Dipole or n J. Org. Chem. 2013, 78 (5) 2099-2103
59. Deane, C. M.; Allen, F. H.; Taylor, R.; Blundell, T. L. Carbonyl-carbonyl interactions stabilize the partially allowed Ramachandran conformations of asparagine and aspartic acid Protein Eng. 1999, 12 (12) 1025-1028
60. Pinto, D. J. P.; Smallheer, J. M.; Cheney, D. L.; Knabb, R. M.; Wexler, R. R. Factor Xa Inhibitors: Next-Generation Antithrombotic Agents J. Med. Chem. 2010, 53, 6243-6274
61. Wong, P. C.; Luettgen, J. M.; Rendina, A. R.; Kettner, C. A.; Xin, B.; Knabb, R. M.; Wexler, R.; Priestley, E. S. BMS-593214, an active site-directed factor VIIa inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studies Thrombosis and haemostasis 2010, 104 (2) 261-269
62. Avdeef, A.; Nielsen, P. E.; Tsinman, O. PAMPA - a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates Eur. J. Pharm. Sci. 2004, 22 (5) 365-374
63. Kimura, R. Refining active sites of GPCR models through balloon expansion, Abstracts, 39th Middle Atlantic Regional Meeting of the American Chemical Society, Collegeville, PA, United States, May 16-18; American Chemical Society: Washington, DC, 2007; MARM-309.
64. Kingsley, L. J.; Lill, M. A. Ensemble generation and the influence of protein flexibility on geometric tunnel prediction in cytochrome P450 enzymes PloS One 2014, 9 (6 e99408
65. Campbell, A. J.; Lamb, M. L.; Joseph-McCarthy, D. Ensemble-Based Docking Using Biased Molecular Dynamics J. Chem. Inf. Model. 2014, 54 (7) 2127-2138
66. Rezaie, A. R.; Fiore, M. M.; Neuenschwander, P. F.; Esmon, C. T.; Morrissey, J. H. Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody Protein Expression Purif. 1992, 3 (6) 453-460
67. Mayer, M.; Meyer, B. Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy Angew. Chem., Int. Ed. 1999, 38 (12) 1784-1788
68. Nicolaisen, E. M.; Petersen, L. C.; Thim, L.; Jacobsen, J. K.; Christensen, M.; Hedner, U. Generation of Gla-domainless FVIIa by cathepsin G-mediated cleavage FEBS Lett. 1992, 306 (2-3) 157-160
69. CNX; Accelrys, I., 5005 Wateridge Vista Drive, San Diego, CA 92121, USA; accelrys.com.
70. Quanta; Accelrys, I., 5005 Wateridge Vista Drive, San Diego, CA 92121, USA; accelrys.com.
71. Bricogne, G.; B. E; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. BUSTER version X.Y.Z. Global Phasing Ltd, Cambridge, United Kingdom, 2011.
72. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66 (4) 486-501
73. Czodrowski, P.; Sotriffer, C. A.; Klebe, G. Protonation Changes upon Ligand Binding to Trypsin and Thrombin: Structural Interpretation Based on pKa Calculations and ITC Experiments J. Mol. Biol. 2007, 367 (5) 1347-1356
74. Glunz, P. W.; Zhang, X.; Zou, Y.; Delucca, I.; Nirschl, A. H.; Cheng, X.; Weigelt, C. A.; Cheney, D. L.; Wei, A.; Anumula, R.; Luettgen, J. M.; Rendina, A. R.; Harpel, M.; Luo, G.; Knabb, R.; Wong, P. C.; Wexler, R. R.; Priestley, E. S. Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 5244-5248
75. Prime, version 1.5112, Schrodinger, LLC, New York, NY, 2006.
76. Bochevarov, A. D.; Harder, E.; Hughes, T. F.; Greenwood, J. R.; Braden, D. A.; Philipp, D. M.; Rinaldo, D.; Halls, M. D.; Zhang, J.; Friesner, R. A. Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences Int. J. Quantum Chem. 2013, 113 (18) 2110-2142